Resverlogix Corporation
4820 Richard Road SW
Suite 300
Calgary
Alberta
T3E 6L1
Canada
Tel: 403-254-9252
Fax: 403-256-8495
Website: http://www.resverlogix.com/
Email: info@resverlogix.com
250 articles about Resverlogix Corporation
-
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
9/28/2022
Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to COVID-19 will focus on the prevention and treatment of Post COVID-19 Conditions (PCC), colloquially known as long-COVID, as opposed to hospitalized COVID-19 patients, reflecting the compelling opportunity for apabetalone to benefit PCC patients and guidance from the US Food and Drug Administration (FDA).
-
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
8/22/2022
Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “ Reduction in the Risk of Major Adverse Cardiovascular Events with the BET Protein Inhibitor Apabetalone in Patients with Recent Acute Coronary Syndrome, Type 2 Diabetes, and Moderate to High Likelihood of Non-Alcoholic Fatty Liver Disease ” in the American Journal of Preventive Cardiology.
-
Resverlogix Announces Appointment of New Chief Scientific Officer
8/15/2022
Resverlogix Corp. announced the appointment of Dr. Ewelina Kulikowski, Ph.D. as Chief Scientific Officer. Dr. Norman Wong is retiring as CSO.
-
Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders
6/22/2022
Resverlogix Corp. held its Annual Meeting of Shareholders in Calgary, Alberta.
-
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors
6/8/2022
Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “ Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators ” in the journal Biomedicine & Pharmacotherapy.
-
Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study
5/9/2022
Resverlogix Corp. today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s request for a Type C meeting to review the clinical trial protocol for its Phase 3 study of apabetalone in high-risk COVID-19 outpatients.
-
Resverlogix Announces One-Year Extension of Debenture.
4/19/2022
Resverlogix Corp. announced that it has closed a one-year extension of Company’s US$6.0 million 10% secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd., and payment of accrued interest thereon, extending the maturity date to May 13, 2023.
-
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
3/17/2022
Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “ BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Study ” in the prestigious American Journal of Respiratory and Critical Care Medicine – which has an impact factor of 21.4.
-
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada
2/17/2022
Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that the first Brazilian site has been initiated for its Phase 2b study to evaluate the safety and efficacy of Canadian-developed apabetalone as a potential oral treatment for COVID-19.
-
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
1/18/2022
Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton.
-
Resverlogix Announces Corporate Update Webcast and Conference Call
12/13/2021
Resverlogix Corp. announced that they will be hosting a corporate update webcast and conference call on Thursday, December 16th, 2021 at 2:00 pm MST.
-
Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients
11/3/2021
Resverlogix Corp. is pleased to announce today that it has entered into a cooperation agreement with the Supreme Council of the Arab-African Economy
-
Resverlogix to Present at Upcoming Conferences - Oct 13, 2021
10/13/2021
Resverlogix Corp., a world leader in epigenetics or gene regulation, announces that President and CEO Donald McCaffrey will be presenting virtually at the following conferences.
-
Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
10/12/2021
Resverlogix Corp., announces the approval of its COVID-19 clinical trial of apabetalone by the Health Research Ethics Board – Biomedical Panel at the University of Alberta.
-
Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
9/8/2021
Resverlogix Corp., a world leader in epigenetics, or gene regulation, announces that its investigational epigenetic therapeutic apabetalone met the primary endpoint in an investigator led pulmonary arterial hypertension pilot study, successfully completing the APPROACH-p trial.
-
Resverlogix Announces Management Change - July 06, 2021
7/6/2021
Resverlogix Corp. announced that Ken Lebioda is stepping down as Senior Vice President, Business and Corporate Development, effective immediately.
-
Resverlogix Announces Voting Results from the 2021 Meeting of Shareholders
6/23/2021
Resverlogix Corp. held its Annual and Special Meeting of Shareholders in Calgary, Alberta.
-
Resverlogix Announces US$6 Million Debenture Financing
5/5/2021
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has entered into an investment agreement with a subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (“Hepalink”) which provides for Hepalink to purchase 10% secured convertible debentures of the Company in the aggregate principal amount of US$6 million
-
New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19Apabetalone treatment reduces SARS-CoV-2 infectivity and completely prevents cardiac damage in a cytokine-storm model
3/3/2021
Resverlogix Corp. and QIMR Berghofer Medical Research Institute, one of Australia’s most successful medical research institutes, announced the publishing of a new article providing evidence of apabetalone’s potential benefit on SARS-CoV-2.
-
Resverlogix Reschedules Update Webcast and Conference Call
1/27/2021
Resverlogix Corp. (“Resverlogix”, or the "Company") (TSX:RVX) announces that it has postponed the webcast and conference call, previously scheduled for January 28 th , 2021, by one week to February 4 th , 2021 at 10:00 am MT.